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Abstract Despite availability of effective treatments for nicotine addiction, smoking remains prevalent with serious
health consequences.Most smokersrecognize the ill effects of smokingbut are unable to quit.Nicotine addictionmaybe
viewedas anyotherchronic illness thatresults fromexposureto a recognizable agent (tobacco) andmanifestswith awell-
documented setof signs and symptoms.Muchlike anychronicdisease, bothenvironmental andgenetic factors determine
the occurrence and severity of this affliction.There has been recent focus on uncovering the genetic basis of nicotine
addiction. In this article, we have attempted to briefly review the current evidence for the role of genetics in smoking as
well as comment on available pharmacotherapeutic options for treating nicotine dependence. r 2003 Elsevier Science Ltd.
Allright reserved.
doi:10.1053/rmed.2002.1443, available online at http://www.sciencedirect.com
Keywords smoking cessation; tobacco; nicotine replacement therapy; genetics; Bupropion.INTRODUCTION
Smoking is the most common cause of avoidable
illness and death in the US. In 1999, an estimated
46.5 million adults (23.5%) were current smokers (1).
An additional 45.7 million are former smokers (1).
One-third of all smokers in this country will die pre-
maturely because of the harmful consequences of
tobacco use. It is a testament to the power of nicotine
addiction that millions of tobacco users have been
unable to save themselves from the consequences of
smoking despite the widespread recognition of its
health e¡ects.
Chronic, morbid tobacco use may be thought of as a
disease entity characterized by a recognized etiologic
agent, nicotine, and a consistent and reproducible set of
signs and symptoms.Nicotine addiction, most frequently
manifested as the smoking behavior accompanied by aReceived 20 August 2002.
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E-mail: frank.leone@mail.tju.edureluctance to quit, has many features of a chronic dis-
ease. Following initiation, nicotine addiction progresses
slowly to its maximum severity, has the potential for
life-long duration, and is characterized by a cycle of re-
mission and relapse despite e¡ective treatment. Epide-
miological data suggest that most smokers would like
to quit smoking. Although more than 70% of smokers
want to quit, fewer than10% of these quit attempts are
successful (2).
This disconnect between the obvious health
consequences of continued smoking and the inability
of smokers to stop breeds frustration and disappoint-
ment among providers (3). Classi¢cation of tobacco
use as a chronic disease can help physicians understand
its relapsing nature, and more importantly, the need
for long-term management goals. Within a chronic
disease paradigm, relapsing tobacco use need not
re£ect failure on the part of either the patient or
the physician, but re£ects only the nature of the
disease. A more complete understanding of the biologi-
cal determinants of tobacco usemay empower clinicians
to take a more proactive approach to implementing
the current guidelines for treating tobacco use and
dependence.
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Despite extensive exposure to and widespread experi-
mentation with nicotine, it is di⁄cult to explain why
some people become nicotine dependent, while others
develop a pattern of occasional use and still others avoid
it entirely.These di¡erences in an individual’s susceptibil-
ity to nicotine dependencemaybe due to environmental
or genetic factors. Fisher ¢rst suggested hereditary in-
£uences on cigarette smoking more than 40 years ago
(4,5).More recent advances in the ¢eld of behavioral ge-
netics andmolecular biology have yielded important evi-
dence supporting the notion of inheritable risk factors
for nicotine dependence.Various models have been used
to study the genetic contribution to the smoking beha-
vior, including twin/adoption studies, animal studies on
inbred, transgenic and gene knock-out animals, associa-
tion studies comparingunrelated a¡ected anduna¡ected
individuals, andmore recently, linkage analysis studies of
the inheritance pattern of speci¢c genotypes (6).
Twin studies usually measure concordance for a given
trait. If the concordant fraction of monozygotic (MZ)
twins is greater than concordant fraction of dizygotic
(DZ) twins, there is likely a genetic in£uence for that
trait.No observable di¡erence in the concordance rates
between MZ and DZ twin pairs suggests that environ-
mental in£uences on behavior are dominant. The pro-
portion of phenotypic variation attributed to genetic
variation, or heritability index, can then be calculated.
Increased concordance for the overall smoking beha-
vior among MZ twins was ¢rst described in1958 (5). In a
review of 18 subsequent twin studies, Hughes demon-
strated that concordance for smoking was consistently
greater inMZ than in DZ twin pairs (7).Heritability esti-
mates among twins in a Swedish population cohort sug-
gested a heritability of 51% for the ever/never smoked
phenotype (8). As a point of reference, genetic analysis
of several aspects of smoking behavior was assessed in a
cohort of over 4000 male twin pairs in the National
Academy of SciencesFNational Research Council Twin
Registry. The concordance rate was higher among MZ
twins than among theDZ twins for thosewho had never
smoked (odds ratio (OR) 1.38, 95% con¢dence interval
(CI), 1.25^1.54), former smokers (OR 1.59, 95% CI 1.35^
1,85), and for current cigarette smokers (OR1.18, 95% CI
1.11^1.26). MZ twins were more likely than DZ twins to
be concordant for quitting smoking (OR 1.24, 95% CI
1.06^1.45) (9,10).
Heath et al. analyzed twin data regarding the initiation
of smoking and found a signi¢cant genetic in£uence on
the risk of becoming a smoker. In U.S. samples, the herit-
ability estimates were 60% in men and 51% in women
while in an Australian sample, heritability estimates
were 33 and 67%, respectively (11). A signi¢cant genetic
impact on smoking persistence was also identi¢edamong twin pairs agedgreater than 30 years, accounting
for 53% of the variance. This e¡ect on smoking persis-
tencewas found tobe independentof e¡ects on initiation
(12). Overall, heritability estimates for initiation range
from 46 to 84%, and for persistence of smoking from 53
to 70% (13^17).
It is impossible to systematically design human inter-
ventional studies examining the genetic in£uences on
the biological mechanisms leading to drug dependence.
However, animal studies make it possible to identify and
characterize the responsible genes and gene products in
a more controlled way. Members of an inbred strain of
animals arehomologous at all genetic loci, and are similar
to MZ twins in that all members of a strain are geneti-
cally identical to all other members. Investigators, using
inbred strains, have ascertained that animals di¡er in
their sensitivity to di¡erent e¡ects of nicotine (18,19).
Marks et al. measured the e¡ect of nicotine on locomo-
tor activity, body temperature, respiratory rate and
acoustic startle response in four inbred mouse strains
and found qualitative andquantitative di¡erences in their
response (20). Further study of these di¡erences re-
vealed that nicotine-sensitive strains developed toler-
ance at a dose that was much lower than that required
for eliciting the same response in the nicotine-resistant
strains, suggesting a relationship between tolerance to
nicotine and initial sensitivity.To the extent towhich this
concept may be generalized to humans, observable dif-
ferences in clinical nicotine dependence may be due to
di¡erences in nicotine sensitivity, i.e. the individual’s
tolerance to the behavioral and physiological e¡ects of
nicotine.
Dopamine release in the nucleus accumbens is the
principalmediator of the rewardmechanism formost of
the drugs abused by humans (21,22). Addictive drugs sti-
mulate a neural ‘‘reward pathway’’ within the limbic sys-
tem of thebrain, themost important of which originates
in the ventral tegmental area (VTA) of the midbrain and
projects to forebrain structures including the prefrontal
cortex and to limbic areas such as the olfactory tubercle,
the amygdala, the septal region and the nucleus accum-
bens.Nicotine has been shown to increase dopaminergic
neurotransmission in the nucleus accumbens in animals
(21), and destruction of the mesolimbic system attenu-
ates the rewarding e¡ects of intravenous nicotine.
Nicotine is known to activate nicotinic acetylcholine
receptors, many of which are located on presynaptic do-
paminergic projections fromVTA to nucleus accumbens
(23). There are many inheritable in£uences on dopami-
nergic neurotransmissionwith identi¢ed polymorphisms
(Fig.1).
The two main classes of dopamine receptors have
been labeled D1 (with subtypes DRD1 and 5) and D2
(subtypes DRD2, 3 and 4) (24). Polymorphism of each
of the dopamine receptor genes have been identi¢ed
and studied in various diseases involving dopamine
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FIG. 1. Biological e¡ects of nicotine on dopaminergic neuro-
transmission.Nicotine acts on nicotinic acetylcholine receptors
and increases dopaminergic neurotransmission by increasing sy-
naptic dopamine release. Studies have looked at polymorphisms
of genes controlling nicotine and dopamine metabolism in nico-
tine addiction. Nicotine is metabolized in liver by enzymes
CYP2A6 and CYP2D6.Polymorphisms in these enzymes a¡ect
amount of available nicotine after smoking.Dopamine transpor-
terprotein anddopaminemetabolismregulate amountof synap-
tic dopamine. Polymorphisms in dopamine receptors a¡ect
number and binding a⁄nity of postsynaptic receptors and thus
dopaminergic neurotransmission.
NICOTINEADDICTION 297neurotransmission.Noble et al. reported that the preva-
lence of DRD2*A1allele was highest in current smokers,
lowest in non-smokers (25). In a case^ control study of
312 non-Hispanic Caucasians who smoked at least a pack
of cigarettes per day, had unsuccessfully attempted to
stop smoking, and were free of other drug dependence,
48.7% carried the A1allele of the DRD2 gene, compared
to 25.9% of 714 non-smoking controls (Po108) (26).
There was also a signi¢cant, inverse relationship be-
tween the prevalence of the DRD2*A1allele and the age
of onset of smoking (P=0.02), and themaximumduration
of time the smokers had been able to quit smoking on
their own (P=0.02). Singleton et al. however did not ¢nd
an increase in allele A1 frequency when comparing smo-
kers with non-smokers (27). The disparity in results
may be due to di¡erent ethnic backgrounds of the study
population with varying degrees of disequilibrium with
other genetic loci.
Dopamine transporter is a protein product of the
SLC6A3 gene.Genetic variations in the dopamine trans-
porter gene may in£uence concentrations of, and re-
sponses to, synaptic dopamine. The SLC6A3 gene has a
30 variable number tandem-repeat polymorphismwithinthe population (28). The SLC6A3-9-repeat allele has
been associated with cocaine-induced paranoia, a disor-
der of dopamine excess (29), while the SLC6A3-10-re-
peat allele has been associated with both attention
de¢cit disorder (30) and Tourette’s syndrome (31), condi-
tions associatedwith insu⁄cient synaptic dopamine. In a
study involving 289 smokers and 233 non-smoking con-
trols, smokers were signi¢cantly less likely to have the
SLC6A3-9 genotype, suggesting increased synaptic do-
pamine may be protective against sustained smoking
(32).Of note, smokers in this study with the SLC6A3-9
genotypewere less likely to have started smoking before
age16. In another case^ control study, Sabol et al. exam-
ined smoking behavior andpersonality traits in a diverse
population of non-smokers, current smokers, and for-
mer smokers (33).Their data showed that there was no
association between the SLC6A3 genotype and smoking
initiation (P=0.32), but instead therewas a signi¢cant as-
sociationwith likelihood of smoking cessation (P=0.025).
Participants with SLC6A3-9 genotype were approxi-
mately 1.5 times more likely to have quit smoking than
subjects without this allele. The possible confounding
role of personality traits in the association between the
SLC6A3 gene and smokingbehavior was testedusing the
Temperament and Character Inventory. The SLC6A3-9
polymorphism is also associated with low scores for
novelty-seeking behavior making it possible that the
observed protective e¡ect may be in part mediated
through its e¡ect on behavioral characteristics.
The dominantmetabolic pathway for nicotine involves
a cytochrome P450 enzyme designated CYP2A6. Two
variant CYP2A6 allele, designated CYP2A6*2 and *3,
have been identi¢ed and both are associated with
reduced metabolic activity. Carriers of the CYP2A6*2
or *3 alleles are both less likely to smoke, and likely to
smoke fewer cigarettes per week if they do, than car-
riers of the CYP2A6*1wild-type allele (34).TheCYP2D6
enzyme is also important in nicotine metabolism.While
the associationbetweenCYP2D6 genotype and smoking
status remains uncertain, there is a relationship to the
degree of physical dependence on nicotine, as measured
by the Fagerstrom Tolerance Questionnaire (FTQ)
(35, 36)
TREATINGTOBACCOUSEAND
DEPENDENCE
More than a simple bad habit, more than a social pro-
blem, tobacco use is the behavioral manifestation of the
convergence of a very complex setof inheritable risk fac-
tors and the exposure to a widely pervasive etiologic
agent. Aswe advance our understandingof thebiological
in£uences on smoking,wemaybegin to understand their
clinical correlates, leading tomore e¡ective and targeted
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FIG 2. The‘4As’and‘5Rs’strategyrecommendedby AHRQ.
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The US Public Health Service clinical practice guide-
line,‘‘TreatingTobacco Use and (Nicotine) Dependence’’,
emphasizes the importance of addressing nicotine de-
pendence as a chronic condition that often requires re-
peated interventions. There is a strong dose^response
relationship between the intensity of physician involve-
ment and its e¡ectiveness (37). Pharmacotherapy is ef-
fective and should be o¡ered to all patients attempting
to quit smoking. Patients unwilling to attempt quitting
should be given a brief intervention designed to increase
their motivation to quit. Systems for consistent identi¢-
cation and documentation of smoking status, and e⁄-
cient treatment of tobacco use, should be incorporated
into every health-carepractice.Tobacco use treatment is
both more clinically e¡ective and more cost-e¡ective
than many other medical treatments emphasized at the
bedside (38,39).
Assessment of tobacco use
At least 70% of smokers see a physician each year, and
more than 50% see a dentist (40^42).Brief, simple physi-
cian advice to quit smoking increases the likelihood that
a smoker will successfully quit and remain a non-smoker
12months later (37).Unfortunately, more than one-third
of current smokers report never having been asked
about smoking status nor urged to quit (43,44). In a
population-based survey, only 15% of smokers received
assistance in smoking cessation and only 3% received fol-
low-up appointment to address nicotine addiction (45).
Interventions
The ¢rst step in treating tobacco use is to ask patients if
they are tobacco users. Simple o⁄ce systems, like ex-
panding the vital signs to include smoking status, drama-
tically increase the rate of intervention (46^48). All
physicians should advise their smoking patients to quit
and assess willingness to quit at that time. Patients un-
willing to quit should be motivated to do so, generally
by highlighting the relevance of tobacco use to their
own personal condition, and expressing concern about
their continued health. Brief interventions to increase
motivation to quit should be organized around the
Agency for Healthcare Research and Quality (AHRQ)
recommended ‘‘5R’s’’ strategy: Relevance (Why is quit-
ting cigarettes personally relevant to you?), Risks (What
are the other possible harmful e¡ects of smoking?), Re-
wards (What are thebene¢ts youwill derive from smok-
ing cessation?), Roadblocks (Are there any obvious
impediments or barriers to quitting that must ¢rst be
addressed?), and Repetition (Whynot try again?) (Fig. 2).Individuals willing to quit smoking should be assisted
with every quit attempt. The most common, but least
e¡ective, method of smoking cessation is sudden, impul-
sive withdrawal, without any pharmacological support,
also referred to as ‘‘cold turkey’’. The success rate with
this method is low and patients experience considerable
nicotine withdrawal symptoms. Almost all smokers try-
ing to quit should receive pharmacotherapy. Exceptions
include patients with absolute medical contraindications
to therapy, and persons suspected of having very low le-
vel or no nicotine dependence at all.
Nicotine replacement therapy (NRT) provides an al-
ternative source of nicotine to the smoker, and helps
prevent severe nicotine withdrawal symptoms during
cessation.There are currently four formulations of nico-
tine available for replacement, the nicotine patch, gum,
inhaler, and nasal spray (Table 1). Using NRT increases
the odds of smoking cessation1.7 times over control and
decreases severity of nicotinewithdrawal symptoms (49,
50).When used properly, all forms of NRTare safe, and
contrary to popular misconceptions, do not increase
the risk of acute myocardial infarction, even when used
during cigarette smoking (51).
Bupropion SR (ZybanTM) is the ¢rst non-nicotine con-
taining medication approved by the FDA for smoking
cessation. It is a non-tricyclic antidepressant that acts
by inhibiting uptake of dopamine and norepinephrine
from the neuronal synapse. Sustained release Bupropion
is e¡ective for smokingcessation andis accompaniedby a
reduction in associated weight gain (52,53).Unlike NRT,
TABLE 1. Pharmacotherapyof smokingcessation
Name (Abstinence rates)
(54)
Dose and duration Adverse e¡ects/precautions Tradename/availability/
pricing
Nicotine patch
17.7 (16.0^19.5)
(Placebo=10.0)
21mg/24 h 4wk
14mg/24 h 2wk
7mg/24 h 2wk
Lower startingdose if
smokingless than 12pack/d
cigarettes
Local skin irritation
Pregnancy:FDAclass C
Caution inpatientswith
arrhythmias andunstable
angina
Nicotrols,Nicoderm CQs
and Habitrols
Available OTC
Approx. cost $48/14 patchpack
Nicotine Gum
(Nicotine polacrilex)
23.7 (20.6^26.7)
(Placebo=17.1)
2^4mgasneeded for cravings
(up to 24 pieces/d)
Pregnancy:FDAclass D
Caution inpatientswith
arrhythmias andunstable angina
Nicorettes
Available OTC
Approx. cost $28/48 gum
pack
Nicotine Inhaler
22.8 (16.9^29.2)
(Placebo=10.5)
6^16 cartridges/d
Each cartridge delivers 4mg
of nicotine over 80 inhalations
Local irritation, cough, rhinitis
Pregnancy:FDAclass D
Caution inpatientswith
arrhythmias andunstable angina
Nicotrol inhalers
Prescription only
Approx. cost $40/42
cartridges
Nicotine Nasal
Spray
30.5 (21.8^39.2)
(Placebo=13.9)
0.5^1mg/nostril/hr
(Max 40 doses/d)
Modto severe irritation
Pregnancy:FDAclass D
Caution inpatientswith
arrhythmias andunstable angina
Nicotrol NSs
Prescription only
Approx. cost $40 ea.
Bupropion SR
30.5 (23.2^37.8)
(Placebo=17.3)
150mgqam 3d then150mg
b.i.d. till 7^12 wkafterquitting
Can also be used for
maintenance therapy
(150mgb.i.d.6 mo)
Insomnia,Drymouth
Pregnancy:FDAclass B
Contraindications: seizure
disorder,Eatingdisorders anduse
of MAOinhibitors
Zybans
Prescription only
Approx. unitcost $2.0 ea
Clonidine
25.6 (17.7^33.6)
(Placebo=13.9)
0.15^0.75mg/d PO
OR
0.10^0.20mg/d transdermal
(TTS)
Hypotension
Pregnancy:FDAclass C
Reboundhypertension if
stopped suddenly
Catapress
Prescription only
Nortriptyline
30.1 (18.1^41.6)
75^100mg/d Tachycardia, seizures,
myocardial infarction
Pregnancy:FDAclass D
Contraindicatedwith MAO
inhibitors
Pamelors
Prescription only
NICOTINEADDICTION 299patients should begin Bupropion SR about 7^10 days be-
fore the quit date. Bupropion SR is more e¡ective than
NRT alone, and may be most e¡ective when combined
with NRT. It is contraindicated in patients with seizure
disorder, eating disorders, uncontrolled hypertension,
and in patients taking MAO inhibitors.When used prop-
erly, it is a safe medication, with the most common side
e¡ects including insomnia,mild agitation, anddrymouth.
Counseling and behavioral therapy play an important
role in smoking cessation. Practical counseling techni-
ques involve teaching smokers to identify situations that
increase their risk of smoking or relapse, and developing
skills to cope with these situations. Excellent written
materials are available through voluntary health organi-
zations such as the American Lung Association (http://
www.lungusa.org) that can help busy clinicians educatepatients in simple and practical ways.Creating an atmo-
sphere that allows free, non-judgmental communication
between the patient and the physician encourages
the patient to talk about their cessation di⁄culties and
relapses, and facilitates the quitting process.
Since nicotine dependence has a chronic relapsing nat-
ure, it is important for physicians to arrange for follow-
up relapse prevention visits. These interventions can be
delivered during a scheduled clinic visit or via telephone.
All ex-smokers should be congratulated on their success
and advised to remain abstinent. Patients should be en-
couraged to communicate their concerns, and potential
factors that threaten abstinence should be identi¢ed and
addressed.Relapses are at the biological core of nicotine
dependence, and do notre£ect a lackof patient determi-
nation, nor failure on the part of the physician.
300 RESPIRATORYMEDICINEInterventions for smoking cessation are both cost-ef-
fective and increase the likelihood of sustained quitting.
Tobacco use can and should be considered a diagnosis
(ICD-9 code 989.84:Toxic e¡ects of tobacco) rather than
simply a risk factor for disease. Clinicians should con-
stantly remind themselves to screen patients for it and
institute appropriate treatment. Future e¡orts should
be directed at expanding the scope of tobacco interven-
tion e¡orts and making it an integral part of the health-
care system.
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